Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models

Glioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis. HET0016 is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth. Therefore, to explore novel treatments, we have generated an improved intravenous (IV) formulation of HET0016 with HP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Jain, Meenu, Gamage, Nipuni-Dhanesha H., Alsulami, Meshal, Shankar, Adarsh, Achyut, Bhagelu R., Angara, Kartik, Rashid, Mohammad H., Iskander, Asm, Borin, Thaiz F., Wenbo, Zhi, Ara, Roxan, Ali, Meser M., Lebedyeva, Iryna, Chwang, Wilson B., Guo, Austin, Bagher-Ebadian, Hassan, Arbab, Ali S.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5282583/
https://ncbi.nlm.nih.gov/pubmed/28139732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep41809
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados